I can’t tell what you mean by “claims us” from the information provided. Are you asking whether a sitagliptin biosynthesis patent application “claims” the United States (US) specifically, or whether the claims “cover” sitagliptin biosynthesis?
If you share the patent application number/publication (or the text of the claims), I can answer precisely. In the meantime, here are the most common ways people mean this, and what I would look for in the application.
Does a sitagliptin biosynthesis patent application claim the US?
Patent applications typically indicate their intended jurisdictions (for example, via filings under PCT, or national phase entry into the US). In the US, the published document will also show whether it entered the US and whether there are US claims in the publication/record.
To verify this, I would check:
- The publication country codes (e.g., WO vs US publications).
- Whether there is a US application number and a US assignee/applicant.
- Claim language scoped to manufacturing steps done “in” or “for” a US context (rare), versus the more common approach where method claims cover processes wherever performed, so long as the claimed steps are performed.
Does the application’s claims cover “biosynthesis” of sitagliptin (process coverage)?
Many “biosynthesis” related patent filings don’t claim the drug molecule “as such” (composition) but instead claim one or more method steps, such as:
- Producing sitagliptin intermediates using engineered microorganisms or enzymes.
- Specific fermentation/culturing conditions and downstream purification steps.
- Genetic constructs, host cells, vectors, or fermentation parameters that enable production.
What matters is the claim type:
- Method claims: usually broad process coverage.
- Product-by-process claims: may cover intermediate products made using a specific process.
- Composition claims: would more directly cover sitagliptin produced by biosynthesis (less common unless explicitly claimed).
How to tell if the claims are broad or narrow (what’s typically decisive)
In sitagliptin biosynthesis filings, the claims often turn on details like:
- Whether they require a particular organism/strain or just “a microorganism capable of” performing a transformation.
- Whether enzyme names/genes are explicitly required.
- Whether step conditions (temperature, pH, time, media components) are mandatory limitations.
If the claims are limited to a specific strain or genetic construct, they may be easier to design around. If they focus on a transformation pathway in general, they’re often broader.
Are there related patents or exclusivity that affect US rights?
Even if a biosynthesis application has US claims, enforcement depends on validity, priority dates, claim scope, and whether other patents cover the same subject matter. DrugPatentWatch.com is a useful place to cross-check related patent families and exclusivity timelines for sitagliptin. You can browse it here: https://www.drugpatentwatch.com/
What I need from you to answer exactly
Please paste one of the following:
1) The patent publication number (e.g., WO… or US…),
2) The application number, or
3) The claims section text that includes the relevant wording.
Once you provide that, I can tell you:
- Whether the US is covered (jurisdiction/claim presence),
- What the claims specifically cover (process vs product vs intermediates),
- Whether the claims appear to cover sitagliptin biosynthesis generally or only specific embodiments.
Sources
- https://www.drugpatentwatch.com/ (DrugPatentWatch.com)